|
THE JENEX CORPORATION
May 19, 2005
Burlington, Ontario
THE JENEX CORPORATION (“Jenex”) (TSX Venture Exchange – JEN), Michael Jenkins, President and CEO of Jenex announces that the loan and warrant transaction announced in our April 29, 2005 Press Release has closed. The amount of the bonus was increased to 1,250,000 Warrants exercisable at $0.14 per common share within 12 months of closing issued as bonus warrants in conjunction with a commercial loan which was increased to $500,000. The Warrants and the common shares issuable on exercise are subject to a hold period until September 19, 2005.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy technology. Patents in the United States, Canada, Australia, and Europe protect the technology. The first device developed from this technology is the Therapik® product, for insect stings and bites. Therapik® has been approved as a Class II medical device in Canada and the United States. In 2004 , Jenex signed an exclusive multi-year licensing agreement for Therapik® for 22 Asian countries. Licensing partners are being pursued for other world markets. The second device, interceptCS™ is the first product proven and approved to prevent cold sores. Jenex has been approved to market interceptCS in Canada with its approved claim, "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks". The Corporation is preparing for the launch of interceptCS in the Canadian market in 2005. More information about the Corporation can be found at www.jenexcorp.com .
Enquiries:
Michael A. Jenkins, President
The Jenex Corporation
940 Sheldon Court, Suite 207
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
|
